SLS
SELLAS Life Sciences Group, Inc. NASDAQ Listed Mar 12, 2008$8.05
+3.74%
vs $7.76
Mkt Cap $877.9M
52w Low $1.39
84.1% of range
52w High $9.31
50d MA $6.52
200d MA $3.90
P/E (TTM)
-32.2x
EV/EBITDA
—
P/B
12.4x
Debt/Equity
0.0x
ROE
-37.9%
P/FCF
-30.9x
RSI (14)
38.20
ATR (14)
$0.66
Beta
2.23
50d MA
$6.52
200d MA
$3.90
Avg Volume
10.0M
SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
Times Square Tower · New York City, NY 10036 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 19, 2026 | AMC | -0.06 | -0.05 | +21.0% | 5.20 | +7.7% | -8.5% | +15.1% | -8.8% | +6.0% | -6.6% | — |
| Nov 12, 2025 | AMC | -0.06 | -0.06 | +5.2% | 1.49 | +0.7% | -2.0% | -2.1% | -1.4% | +12.8% | -4.4% | — |
| Aug 12, 2025 | AMC | -0.08 | -0.07 | +16.0% | 1.61 | +0.6% | -3.7% | +0.0% | +5.2% | +6.1% | -1.7% | — |
| May 13, 2025 | AMC | -0.10 | -0.07 | +30.0% | 1.41 | +4.3% | +7.1% | +6.0% | +1.9% | +7.4% | +10.9% | — |
| Mar 20, 2025 | AMC | -0.11 | -0.08 | +27.3% | 1.21 | -6.6% | -0.8% | +2.5% | -0.8% | -3.3% | -1.7% | — |
| Nov 13, 2024 | AMC | -0.13 | -0.10 | +23.1% | 1.27 | +0.8% | +0.0% | +3.9% | -2.3% | +0.0% | -3.9% | — |
| Aug 13, 2024 | AMC | -0.16 | -0.13 | +18.8% | 1.19 | +0.0% | +0.8% | +5.8% | +3.9% | +5.3% | -5.8% | — |
| May 14, 2024 | AMC | -0.16 | -0.21 | -31.2% | 1.37 | -1.5% | +7.3% | +0.0% | -0.7% | +1.4% | -4.1% | — |
| Mar 28, 2024 | AMC | 0.09 | -0.25 | -388.5% | 1.01 | +2.0% | +5.9% | +10.3% | +11.0% | -1.5% | +3.9% | — |
| Nov 9, 2023 | AMC | -0.03 | -0.33 | -1200.2% | 0.91 | -2.2% | -0.2% | -3.1% | +3.1% | +6.9% | -5.1% | — |
| Aug 10, 2023 | AMC | -0.35 | -0.31 | +11.4% | 1.57 | -0.6% | -1.3% | -1.9% | -2.0% | -4.7% | +0.0% | — |
| May 11, 2023 | AMC | -0.29 | -0.47 | -62.1% | 1.71 | -0.6% | -11.1% | +7.9% | -3.7% | +7.0% | +0.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 12 | Maxim Group | Maintains | Buy → Buy | — | $5.48 | $5.52 | +0.7% | -8.2% | +6.8% | -0.2% | -6.0% | -1.8% |
| Jul 16 | Maxim Group | Maintains | Buy → Buy | — | $1.90 | $1.91 | +0.5% | +1.1% | -1.0% | -6.8% | +4.5% | -0.5% |
| Nov 22 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $0.97 | $0.99 | +2.0% | +4.1% | +4.0% | -4.8% | +6.0% | -0.9% |
| Sep 7 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $1.44 | $1.42 | -1.4% | +2.1% | +8.2% | -5.0% | +0.0% | +0.7% |
| Nov 15 | Alliance Global Partners | Maintains | Buy → Buy | — | $2.55 | $2.50 | -2.0% | -12.2% | +9.4% | +7.3% | -1.1% | -0.8% |
| Jun 28 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $2.32 | $2.39 | +3.0% | -4.7% | +2.3% | -1.3% | -1.3% | +7.7% |
| Jul 21 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $8.60 | $9.00 | +4.7% | +8.1% | -3.3% | -2.3% | -1.3% | -2.0% |
| Nov 18 | Alliance Global Partners | Maintains | Buy → Buy | — | $5.15 | $4.23 | -17.9% | -18.4% | +4.5% | -2.1% | -7.0% | -2.0% |
| Nov 18 | Oppenheimer | Maintains | Outperform → Outperform | — | $5.15 | $4.23 | -17.9% | -18.4% | +4.5% | -2.1% | -7.0% | -2.0% |
| Nov 18 | Maxim Group | Upgrade | Hold → Buy | — | $5.15 | $4.23 | -17.9% | -18.4% | +4.5% | -2.1% | -7.0% | -2.0% |
| Nov 18 | Maxim Group | Maintains | Buy → Buy | — | $5.15 | $4.23 | -17.9% | -18.4% | +4.5% | -2.1% | -7.0% | -2.0% |
| Nov 15 | Maxim Group | Upgrade | Hold → Buy | — | $6.17 | $6.25 | +1.3% | -16.5% | -18.4% | +4.5% | -2.0% | -7.0% |
| Apr 8 | Alliance Global Partners | Maintains | Buy → Buy | — | $51.50 | $53.50 | +3.9% | +5.8% | +8.3% | -5.9% | -3.6% | -2.8% |
| Nov 1 | Oppenheimer | Maintains | Outperform → Outperform | — | $61.00 | $73.50 | +20.5% | +36.1% | +7.8% | +3.4% | -4.3% | -1.7% |
| Jul 20 | Maxim Group | Maintains | Buy → Buy | — | $76.50 | $92.50 | +20.9% | +1.3% | -9.0% | -6.4% | -1.5% | -5.4% |
| Apr 2 | H.C. Wainwright | Maintains | Buy → Buy | — | $172.50 | $280.00 | +62.3% | +150.7% | +3.7% | -25.3% | +3.0% | -0.7% |
| Mar 19 | Maxim Group | Upgrade | Hold → Buy | — | $239.50 | $267.00 | +11.5% | -0.8% | -18.5% | +6.2% | +2.2% | -4.3% |
No insider trades available.
8-K
SELLAS Life Sciences Group, Inc. -- 8-K Filing
Jun 2
8-K
Unknown — 8-K Filing
SELLAS anticipates 2026 clinical milestones in its AML programs could validate its late-stage pipeline and potentially drive significant stock movement based on trial progress.
Mar 19
8-K
Unknown — 8-K Filing
This appears to be a technical XBRL metadata filing with no material business information, so it has no direct stock impact—investors should monitor actual 8-K disclosures instead.
Mar 11
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 7,525,929 | $32M | New | Mar 2026 |
| 2 | Marshall Wace, Llp | 2,037,162 | $9M | Added | Mar 2026 |
| 3 | Morgan Stanley | 1,781,858 | $7M | Reduced | Dec 2025 |
| 4 | Vanguard Portfolio Management Llc | 1,462,806 | $6M | New | Mar 2026 |
| 5 | Northern Trust Corp | 1,275,984 | $5M | Added | Mar 2026 |
| 6 | Dagco, Inc. | 1,028,780 | $4M | Added | Mar 2026 |
| 7 | Ubs Group Ag | 745,419 | $3M | Added | Mar 2026 |
| 8 | Invesco Ltd. | 698,080 | $3M | Added | Mar 2026 |
| 9 | Nuveen, Llc | 670,974 | $3M | Reduced | Mar 2026 |
| 10 | Bank Of America Corp /de/ | 641,683 | $3M | Added | Mar 2026 |
| 11 | Bank Of New York Mellon Corp | 478,366 | $2M | Added | Mar 2026 |
| 12 | Two Sigma Investments, Lp | 403,165 | $2M | Reduced | Mar 2026 |
| 13 | Susquehanna International Group, Llp | 397,056 | $2M | Added | Mar 2026 |
| 14 | Everhart Financial Group, Inc. | 364,397 | $2M | Reduced | Mar 2026 |
| 15 | Opus Capital Group, Llc | 346,452 | $1M | Added | Mar 2026 |
| 16 | Simplex Trading, Llc | 295,162 | $1M | New | Mar 2026 |
| 17 | Wells Fargo & Company/mn | 225,707 | $955K | New | Mar 2026 |
| 18 | Millennium Management | 159,524 | $675K | Reduced | Mar 2026 |
| 19 | Profund Advisors Llc | 111,794 | $473K | New | Mar 2026 |
| 20 | Tema Etfs Llc | 90,007 | $381K | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$877.9M
Enterprise Value
$806.0M
P/E (TTM)
-32.20x
Forward P/E
—
PEG Ratio
0.31x
P/B
12.39x
P/S
—
P/FCF
-30.92x
EV/EBITDA
—
Shares Out
109.1M
Financials (TTM)
Revenue
$0
Net Income
-$26.9M
EBITDA
-$28.3M
Free Cash Flow
-$28.4M
Op Cash Flow
-$28.4M
EPS Basic
$-0.25
EPS Diluted
$-0.25
EPS Forward
$-0.28
Gross Margin
0.0%
Op Margin
0.0%
Net Margin
0.0%
Balance Sheet
Total Assets
$78.3M
Total Liab.
$7.5M
Total Equity
$70.9M
Cash
$71.9M
LT Debt
$0
Book Value/Sh
$0.65
Debt/Equity
0.01x
Current Ratio
10.72
Quick Ratio
10.72
Returns & Growth
ROE
-37.9%
ROA
-34.3%
ROIC
-39.3%
Rev Growth YoY
+0.0%
EPS Growth YoY
+50.0%
Price Returns
2W
+25.5%
1M
+88.1%
3M
+88.8%
6M
+474.7%
12M
+444.4%
Technicals
52W High
$9.31
52W Low
$1.39
50d MA
$6.52
200d MA
$3.90
RSI (14)
38.20
ATR (14)
$0.66
Beta
2.23
Avg Volume
10.0M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
4
Ex-Div Date
Mar 24, 2011
Analyst Price Targets
Consensus
$2.80
High
$3.20
Low
$2.40
Median
$2.80
Data updated apr 27, 2026 1:47am
· Source: financialmodelingprep.com